Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny study aims to predict lupus flares before they strike

NCT ID NCT05747651

Knowledge-focused Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study enrolled 6 adults with systemic lupus erythematosus (SLE) to collect blood, urine, saliva, stool, and tissue samples over time. The goal was to find biological markers that could predict when a patient's disease might flare up or how they might respond to treatment. Researchers hope this information will eventually help doctors personalize care for people with lupus.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could lead to better ways to predict lupus flares and personalize treatment, improving long-term outcomes.
What could go wrong
This is a very small, early-stage observational study (6 participants) focused on data collection, not treatment. Results may not apply broadly and require much larger studies to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

6 people

The number who actually took part.

Started

Mar 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

SLE patients with active disease, defined as a BILAG A or B within certain domains (see inclusion criteria) will be included in this study. These patients will either be directly recruited to this study or originate from the "feeding" phase (3TR-SLE, flare biomarker study, NCT05458622) when a flare is detected. There will be no restriction regarding current or previous therapies.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Age at the time of inclusion ≥ 18 years. * 2\. Able to consent and agree to participate in the study. * 3\. Diagnosis of SLE according to the EULAR/ACR criteria. * 4\. Patients should have at least one of the following: i. active arthritis, attributed to SLE (BILAG A or B in the musculoskeletal domain). ii. active skin disease, attributed to SLE (BILAG A or B in the mucocutaneous domain). iii. active biopsy-proven lupus nephritis (LN; ISN/RPS class III, IV or V), with or without extrarenal organ involvement. iv. active CNS involvement as a main manifestation (with or without other organ involvement) along with initiation of new treatment for CNS involvement (BILAG A or B in the neuropsychiatric domain). * 5\. Stable standard therapy for at least 30 days, including hydroxychloroquine (HCQ) or chloroquine treatment, unless contraindicated or documented intolerance. Exclusion Criteria: * 1\. Serological activity only without signs of clinically active disease. * 2\. Pregnancy and/or breastfeeding. * 3\. Unable/unaware to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Systemic lupus erythematosus (SLE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic lupus erythematosus (SLE)

Contacts and locations

Locations

  • CHU Brest

    Brest, France, 29200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.